Dataset Information


What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study.

ABSTRACT: The purpose of this study was to determine the effect of retroperitoneal (RP) exploration on progression-free survival (PFS) and overall survival (OS) in epithelial ovarian cancer (EOC) patients with stage IIIC disease who underwent optimal debulking surgery.Data were collected from records of the Gynecologic Oncology Group 182 (GOG-182) study of stage IIIC EOC patients cytoreduced to no gross residual disease (R0) or minimal gross residual (<1?cm) disease (MGRD) at primary surgery. Patients with stage IIIC disease by intraperitoneal (IP) tumor were included and divided into 3 groups: 1)?>?2?cm IP tumor without lymph node involvement (IP/RP-), 2)?>?2?cm IP tumor with lymph node involvement (IP/RP+), and 3)?>?2?cm IP tumor with no RP exploration (IP/RP?). The effects of disease distribution and RP exploration on PFS and OS were assessed using Kaplan-Meier and proportional hazards methods.There were 1871 stage IIIC patients in GOG-182 who underwent optimal primary debulking surgery. Of these, 689 (36.8%) underwent RP exploration with removal of lymph nodes from at least 1 para-aortic site, and 1182 (63.2%) did not. There were 269 patients in the IP/RP- group, 420 patients in the IP/RP?+?group, and 1182 patients in the IP/RP? group. Improved PFS (18.5 vs 16.0 months; P?

SUBMITTER: Rungruang BJ 

PROVIDER: S-EPMC5339038 | BioStudies | 2017-01-01T00:00:00Z


REPOSITORIES: biostudies

Similar Datasets

2020-01-01 | S-EPMC6959015 | BioStudies
1000-01-01 | S-EPMC4348639 | BioStudies
2017-01-01 | S-EPMC5680503 | BioStudies
2013-01-01 | S-EPMC3619264 | BioStudies
2016-01-01 | S-EPMC5116405 | BioStudies
2018-01-01 | S-EPMC6658709 | BioStudies
2018-01-01 | S-EPMC6035193 | BioStudies
2020-01-01 | S-EPMC7177627 | BioStudies
1000-01-01 | S-EPMC5728317 | BioStudies
1000-01-01 | S-EPMC3539917 | BioStudies